Product Name: FGFR1 (650-657) pY653+pY654
Product Number: PE-04AUF01
Size:      $US
Peptide Name: FGFR1 (650-657) pY653+pY654

Product Use: This phosphopeptide may be useful as a substrate for screening the phosphatase activity of protein phosphatases. The peptide sequence is located in the protein kinase catalytic domain activation T-loop between subdomains VII and VIII. Y653 and Y654 phosphorylation stimulate phosphotransferase activity.

Peptide Production Method: Solid-phase peptide synthesis

Peptide Origin: Homo sapiens

Peptide Sequence: HID(pY)(pY)KKT

Peptide Modifications N Terminus: Free amino

Peptide Modifications C Terminus: Amide

Peptide Modifications Other: Phosphorylated

Storage Conditions: -20°C

Scientific Background: FGFR1 (Flt2) is a protein-tyrosine kinase of the TK group and FGFR family. It is a fibroblast growth factor receptor, and is alternatively spliced generating multiple variants that are differentially expressed during embryogenesis and in the adult body. It is highly expressed and widely distributed in most tested human tissues. FGF receptors plays an important role in multiple biological processes, including mesoderm induction and patterning, cell growth and migration, organ formation and bone growth. FGFR1 is involved in cell proliferation, differentiation, migration, and embryonic development. FGFR1 is activated by basic-FGF, which induces dimerization and transautophosphorylation. Phosphorylation of Y653 and Y654 increases kinase activity. Phosphorylation of Y766 induces interaction of FGFR1 with PLCg1 and SHB, induces FRS2 phosphorylation, and activation of RAS and MAPK signalling, leading to cell proliferation. Phosphorylation of Y154 induces receptor internalization. It can phosphorylate GAB1, PLCG1, FRS2, and SHB. FGFR1 has been linked with the development of Pfeiffer Syndrome (PS), Kallmann Syndrome Type 2 (KAL2), Stem Cell Leukemia Lymphoma Syndrome (SCLL), breast carcinomas (ductal), lung bronchoalveolar carcinomas and lung large cell carcinomas.